Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 38 % of short-term debt in 2024; threshold 65 %.
Financials
Financial year 2024
B&B PHARMA from Beersel, company number BE0554988666, closed financial year 2024 with a result of € 30,221 after tax. For that financial year B&B PHARMA recorded a gross margin of € 138,393 and equity of € 212,233. Compared with financial year 2023, the result moved from € 341,495 to € 30,221. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 19, 2025.
€ 212,233
▼ 44% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 30,221
▼ 91% vs 2023
Profit after tax over the fiscal year.
€ 10,265
▲ 46% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 200,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
Debts at end 2024
€ 461,644
▼ 4% vs 2023
€ 79,960 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 60,810
▲ € 58,396 vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 245
▼ 82% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 164,416 | € 236,558 | € 364,247 | € 138,393 | ▼ 62% |
| Profit after taxes | € 225,734 | € 169,369 | € 341,495 | € 30,221 | ▼ 91% |
| Equity | € 149,147 | € 40,516 | € 382,011 | € 212,233 | ▼ 44% |
| Total debts | € 732,424 | € 823,536 | € 519,923 | € 648,679 | ▲ 25% |
| Cash | € 23,084 | € 15,124 | € 7,028 | € 10,265 | ▲ 46% |
| Land & buildings | € 195,294 | € 183,088 | € 170,883 | € 158,677 | ▼ 7% |
| Retained profit | € 130,547 | € 21,916 | € 363,411 | € 193,633 | ▼ 47% |
| Dividend | € 225,500 | € 278,000 | € 0 | € 200,000 | |
| Bank debt | € 595,631 | € 531,732 | € 480,499 | € 461,644 | ▼ 4% |
| Balance sheet total | € 881,571 | € 864,052 | € 901,935 | € 860,912 | ▼ 5% |
Key figures of B&B PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to B&B PHARMA?
What happened at B&B PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 30,221 (▼ 91% vs 2023). filed late Source: NBB ↗
- New establishment in Ukkel. KBO
- Balthazar Emmanuel became a director. NBB
- Nassima Boulal became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 225,734 profit in 2021 to € 30,221 profit in 2024.
Paid € 208,095 in corporate taxes since 2021.
Best year ever: 2023, with € 341,495 profit.
Paid out € 703,500 in dividends to the owners in total.
A new publication or filing at B&B PHARMA? We notify you, reason included.
Follow B&B PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind B&B PHARMA are Balthazar Emmanuel and Nassima Boulal. It owns 100% of GAMA MEDICAL itself.
Directors
According to the 2024 annual accounts
Balthazar Emmanuel
Director
since 2014
since 2014
Establishments
Establishment units
Physical locations of this company
Blarenveld 18
1650 Beersel
Gulden Kasteelstraat 14
1180 Ukkel
Active since 2 July 2014
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0554.988.666
- VAT number
- BE 0554.988.666
- Registered office
- Blarenveld 18, 1650 Beersel
- Names & denominations
- B&B PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 July 2014
- Peppol
- Active · Active since 6 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings